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Abstract 
Background: People with epilepsy have more concomitant medical conditions than the general 
population; these co-morbidities play an important role in premature mortality. We sought to 
generate explanatory hypotheses about the co-occurrence of somatic co-morbidities and epilepsy, 
avoiding causal and treatment-resultant biases.  
Methods: We collected clinical, demographic and somatic co-morbidity data for 2016 consecutive 
adults with epilepsy undergoing assessment at a tertiary centre and in 1278 people with epilepsy in 
the community. Underlying causes of epilepsy were not classed as co-morbidities.  
Results: Somatic co-morbidities were more frequent in the referral centre (49%) where people more 
frequently had active epilepsy than in the community (36%). Consistent risk factors for co-
morbidities were found in both cohorts.  Using multivariable ordinal regression adjusted for age, 
longer epilepsy duration and an underlying brain lesion were independently associated with a 
smaller burden of somatic conditions.  The treatment burden, measured by the number of drugs to 
which people were exposed, was not an independent predictor. Shorter epilepsy duration was a 
predictor for conditions that conceivably harbour significant mortality risks.  
Conclusions: Somatic co-morbidities do not occur randomly in relation to epilepsy; having more 
severe epilepsy seems to be a risk factor. Independently from age, the early period after epilepsy 
onset appears to be at particular risk, although it is not clear if this relates to an early mortality or to 
a later decrease of the burden of co-morbidities. These results suggest that, for some people, 
epilepsy should be considered a systemic condition not limited to the CNS. 
 
  
Introduction 
Several large community studies using either self-reported diagnoses or registers have shown a 
higher prevalence and incidence of somatic conditions in people with epilepsy than in the general 
population(1-8). Co-morbidities, defined classically as “any additional distinct clinical entity”(9) from 
epilepsy, were found to be increased globally, affecting the majority of conditions assessed in each 
study. There is evidence that this increased prevalence is not fully explained by over-representation 
of unfavourable socio-economic factors among people with epilepsy(10) or reporting bias caused by 
greater contact with medical services(8). Several lines of evidence also confirm that, when excluding 
epilepsy-related health issues, people with epilepsy have a worse health status than people in the 
general population. People with epilepsy have a greater utilisation of healthcare services for co-
morbid conditions(11), incur higher healthcare costs than the general population after excluding 
epilepsy-related costs(12), and have increased premature mortality seemingly unrelated to 
epilepsy(13). 
Most epidemiological studies analysing prevalence of co-morbidities are confounded by causal (some 
co-morbidities may be the cause of epilepsy) and resultant (co-morbidities may be the consequence 
of epilepsy or its treatment) associations(14), lacking data on the temporal course of the conditions. 
These biases do not seem, however, to explain the increased burden of co-morbidities; people with 
epilepsy were shown to be more likely to die prematurely due to cerebrovascular disease, even those 
without a stroke before epilepsy onset(15) and regardless of treatment exposure(7). 
Very little is known about the mechanism(s) underlying the increased burden of somatic co-
morbidities in epilepsy. Migraine with aura, for instance, was shown to have a bidirectional 
association (migraine with aura increasing the risk of developing epilepsy and vice-versa)(16, 17), 
suggesting common underlying risk factors(18). Better understanding of the mechanisms of co-
morbidities could help to prevent morbidity and premature mortality in people with epilepsy. 
We assessed the prevalence and predictors of co-morbid conditions in widely different settings, 
accounting for the whole spectrum of epilepsy, to generate explanatory hypotheses for the increased 
burden of somatic co-morbidities in epilepsy. In contrast to previous studies on co-morbidities, 
availability of medical assessment allowed us to minimise biases due to causes, results and treatment 
of epilepsy, so identifying genuine co-morbidities.  
Methods 
We recorded all current and previous medical and psychiatric diagnoses distinct from epilepsy in two 
different adult populations with epilepsy: people seen at a referral centre and people in the 
community. People seen at the referral centre were included as part of an audit of all people with 
chronic epilepsy admitted to our assessment unit at Chalfont St Peter, UK, over ten years between 
2001 and 2011. People with epilepsy in the community consisted of two groups. The first included 
people enrolled in the National General Practice Study of Epilepsy and Epileptic Seizures (NGPSE) 
study(19), a nation-wide prospective study of people with epilepsy followed by general practitioners; 
we included people with definite and probable epilepsy (according to whether episodes were 
considered as definite or probable epileptic seizures), up to their last available assessment. The 
second group constituted an audit at 10 general practices in the Chilterns region (west of London) in 
2001 and 2002; people were identified through records of antiepileptic drug (AED) prescription; the 
diagnosis of epilepsy was then confirmed through medical records review by a specialist epilepsy 
nurse. At the referral centre, co-morbidities are systemically recorded as part of the admission 
process. Somatic and psychiatric co-morbidity diagnoses relied on diagnoses reported by general 
practitioners or self-reported by the individual; psychiatric co-morbidities were reassessed if needed 
during the assessment in patients at the referral centre. At the referral centre, Somatic conditions 
were not reassessed except for the investigation of the cause epilepsy. Demographic data and 
epilepsy characteristics were recorded in both cohorts. Family history of epilepsy and seizure types 
were also documented in the tertiary centre cohort based on descriptions and, when available, on 
observation and recording. Family history was considered as positive when more than one member 
of the family (genetically related) had/has seizures.  Location of the seizure onset zone in the cohort 
assessed at the referral centre was documented, defined where possible through a combination of 
seizure semiology and EEG recordings. All antiepileptic medications to which the person had been 
exposed were recorded in both populations; AEDs were also classified according to whether they 
significantly induce liver enzymes (phenobarbital, phenytoin, carbamazepine) or not(20). The total 
dose of AEDs to which each person had been exposed was not available; we used the number of 
AEDs over the duration of the epilepsy censored at assessment as a surrogate. Traumatic brain 
lesions that were presumed not to be the cause of the patient’s epilepsy, and conditions that were 
clearly the direct exclusive consequence of traumatic lesions, were not considered as co-morbidities. 
Indirect consequences of traumatic lesions (for instance venous thrombosis after a fracture) would 
be considered as co-morbid. A decision was made to exclude hay fever, appendicectomy, 
tonsillectomy, hysterectomy (without a clear diagnosis, or for premenopausal menorrhagia), and 
unspecified skin conditions (without further details) from the analyses. Those conditions or the 
conditions leading to those procedures were likely to have been reported inconsistently. All 
phenomena considered by the treating consultant to be the direct effect of treatments (such as 
hyponatremia in people taking carbamazepine or kidney stones in those on topiramate) were not 
considered, in order to exclude as far as possible resultant co-morbidities.  
Conditions considered at the assessment to be the causes of epilepsy (genetic or structural) were 
recorded separately to exclude causal co-morbidities. People assessed at the referral centre 
systematically underwent MRI scanning, whereas people in the community had had MRI or CT scans 
or neither. Risk factors for the cause (such cerebrovascular risk factors in stroke) were not considered 
as part of the cause. A structural abnormality was presumed to be the cause of epilepsy when the 
localisation of the seizure onset zone (based on semiology and electrophysiological recording) was in 
keeping with the localisation of the lesion at imaging. Brain injuries (such as meningitis), even if 
leading to minimal structural changes, were considered as structural causes if they occurred before 
seizure onset. As discussed above, traumatic brain injury was considered as the cause of epilepsy 
only if the date of occurrence and localisation with the epilepsy. For cortical development 
malformation, an underlying cause (such a genetic condition reported as causal) was not considered 
as co-morbidity but as part of the cause. Haemorrhagic complications of a vascular malformation 
were not considered as a co-morbidities.  Degenerative conditions or inflammatory conditions (such 
as multiple sclerosis) were considered as a cause only if there was no alternative explanation and the 
disease preceded the onset of epilepsy. Conditions (for example, genetic conditions) where epilepsy 
is commonly encountered were considered as co-morbidity only if seizure semiology and the seizure 
onset zone were exclusively in keeping with another clear focal structural cause of epilepsy. 
Intellectual disabilities were recorded separately and not considered as co-morbidities as seizures 
and causes of epilepsy can account for their occurrence(21). Focal neuropsychometric deficits in 
keeping with the epilepsy focus were also not considered co-morbidities. Genetic conditions were 
considered to be the cause of epilepsy if seizures are widely regarded as a part of the genetic 
syndrome in the OMIM database (http://www.omim.org/) or through a literature review (PubMed). 
Other clear features of a genetic syndrome (angiomyolipoma in tuberous sclerosis, for example) 
were not considered as co-morbid conditions, but as part of the underlying genetic syndrome. 
Genetic generalised epilepsy (idiopathic generalised epilepsy) was not considered as a genetic 
causation of epilepsy as genetic mechanisms are likely to be complex and definitive genetic causes 
have been demonstrated only in a minority of cases(22). 
As in previous studies that considered the whole unselected burden of somatic conditions(4, 11), co-
morbidities were grouped into categories (e.g. circulatory, genitourinary, nervous system) according 
to the WHO International Classification of Diseases and Related Health Problems 10th Revision (ICD 
10) chapters (http://apps.who.int/classifications/icd10/browse/2010/en). Potential predictors with 
small numbers (<15) per outcome category (predictors such as idiopathic epilepsy, genetic cause) in 
the community cohort were not included in the multivariable analyses (supplementary material 2). 
Chi squared and Mann-Whitney tests were used for univariable analysis of predictors of the numbers 
of co-morbidity categories. Multivariable stepwise backward ordinal logistic regression was used to 
analyse the factors influencing the number of systems (none, one, or two or more) affected by co-
morbidities. P values of <0.05 were considered statistically significant overall and variables with 
univariable p value <0.1 were included in multivariable regression. Assumptions (proportionality of 
odds ratios, co-linearity) were checked.  
We sought to adjust for age and found an interaction between age and co-morbidities in the 
community cohort and so the analysis was stratified with a division at 60 years. There was no 
interaction in the referral centre cohort (the cohort was younger on average), so a simple regression 
adjustment for age was used (implemented as [age-mean age]2). 
Multivariable logistic regression was then used to assess the effect of each identified predictor on 
specific co-morbidity categories (yes/no) adjusting for factors found significant in the previous 
analyses. For the analysis of predictors of specific co-morbidity categories, we performed a 
Bonferroni correction for multiple testing. Statistical analyses were performed with SPSS (v20; SPSS 
inc) and Stata (v13; Statacorp Inc.). 
The study was approved by the institutional Ethics Committee.  
 
Results  
We collected data from general practices for 1278 people diagnosed with epilepsy, and from the 
referral centre for 2016 people with chronic epilepsy assessed there. Demographic and clinical data 
for both cohorts are presented in Table 1. At the time of assessment, all people at the referral centre 
had active epilepsy, while 87% of the community cohort had not experienced seizures for at least 
one year. Those at the referral centre had been exposed to a greater number of AEDs than those in 
the community. Among people at the referral centre, 37% (750) had temporal lobe epilepsy, 17% 
(352) frontal epilepsy, 16% (323) multifocal or generalised epilepsy, 0.8% (16) occipital epilepsy and 
0.7% (15) parietal epilepsy; the seizure onset zone could not be determined. 
All conditions considered as co-morbid can be found in supplementary material 1. People at the 
referral centre significantly more often had somatic co-morbidities (49%) than people in the 
community (36%; Table 1). Somatic co-morbidities were significantly more frequent than psychiatric 
ones in both cohorts (36 vs 11% in the community and 49 vs 23% in the referral centre cohort). When 
correcting for age and gender, people from the referral centre were at significantly increased risk to 
have somatic co-morbidities (OR: 2.6, 95% CI: 2.2-3.1, p<0.0001). Functional systems affected by co-
morbid conditions (co-morbidity categories) are shown in Figure 1.   
Predictors of the burden of comorbidity 
Factors associated with the overall burden of co-morbidities are detailed in Table 2 for each cohort. 
Multivariable analyses in both cohorts showed that longer epilepsy duration and presence of an 
underlying brain lesion were independently associated with a reduced burden of somatic co-
morbidities, independently of age (Table 2). In the referral centre, female gender was a significant 
risk factor for a greater burden. The presence of psychiatric co-morbidities was not a significant 
predictor of the burden of somatic co-morbidities for either cohort, neither was localisation of the 
seizure onset zone in the referral centre cohort, nor seizures in the year preceding the assessment in 
the community cohort. The number of AEDs to which individuals were exposed was not a significant 
predictor of the number co-morbidity categories, but the total number of AEDs or of enzyme-
inducing AEDs to which people had ever been exposed were significantly correlated with epilepsy 
duration in both cohorts. 
Predictors of specific comorbidity categories are detailed in Table 3. 
Discussion 
Our study shows that every second person with epilepsy seen at a referral centre and every third in 
the community has at least one somatic co-morbid condition, disregarding causes of epilepsy and 
direct consequences of its treatment. In the only previous study considering all co-morbidities(4), the 
prevalence of all co-morbidities was increased 1.5 fold in people with epilepsy, which is similar to our 
results compared with general population studies using similar methodology(23, 24). Co-morbidities 
can indeed be classified as causing epilepsy, resulting from epilepsy or its treatment, and those with 
no obvious association. Including indiscriminately all concomitant condition would not satisfied the 
original definition of co-morbidities proposed by Feinstein (“distinct additional clinical entity” (9)) as 
causal or resultant conditions are intimately linked with the disease. Studying co-morbidity 
apparently not linked with epilepsy, may allow us to explore if epilepsy has wider implication than 
commonly thought, that may explain the treatment and cause independent premature mortality 
found in this condition (13). We intended to draw out mechanistic hypotheses from the 
epidemiological relationship between epilepsy and co-morbidities, as finding predictors of the 
burden of somatic co-morbidities would provide insight into the co-occurrence of epilepsy and other 
somatic conditions. This was impossible in previous studies (1-8) given the limited data available on 
the conditions reported and epilepsy in the registries or questionnaires. 
The two populations we assessed to explore the spectrum of epilepsy differed widely, in terms of the 
proportion of people in remission and the number of AEDs to which people were exposed. The 
prevalence of somatic co-morbidities was significantly higher in the cohort of people seen at the 
referral centre, despite their younger age. The prevalence of co-morbidities was not, however, 
assessed in exactly the same way in both cohorts (people in the community were followed in general 
practice in the long term without any formal reassessment, while those at the referral centre were 
actively reassessed), but we aimed to reduce bias by discarding conditions potentially not reported 
consistently. A greater prevalence of ECG abnormalities(25), of obesity(26) and a higher mortality 
rate due to cancer(27) have been already reported in people with drug-resistant epilepsy: greater 
exposure to antiepileptic medication has been hypothesised as the explanation. In our study, the 
influence of AEDs was assessed as a global effect, and did not account for the role of specific AEDs in 
particular conditions (such as polycystic ovary syndrome). Treatment burden was correlated with 
epilepsy duration and was not an independent predictor. This is in line with a life-long follow-up 
study(28) where the major determinant of premature mortality due to co-morbidities was seizure 
frequency in people that had similar treatment exposure. We hypothesise that the difference 
between the two cohorts suggest that greater seizure frequency, rather than treatment exposure, 
could be the major determinant of the association of co-morbidities with greater epilepsy severity.  
Many common chronic conditions, such as inflammatory conditions(29), asthma(30), diabetes and 
obesity(31) are associated with significantly increased burdens of cardiovascular conditions and 
cancers compared with the general population. Disease severity in those conditions also seems to be 
a predictor of the occurrence of co-morbidities(32), which are widely considered as the consequence 
of low grade chronic systemic inflammation(33, 34). It is increasingly clear that epilepsy, mostly 
probably as a consequence of seizures, induces a systemic inflammatory response in the long 
term(35). Several clinical studies showed that there is a plasma peak of pro-inflammatory interleukin 
6 after seizures (35-40) lasting up to 72 hours (41). Those changes were also found interictally in 
people with chronic epilepsy (35, 42). Other pro-inflammatory changes, such as increased interleukin 
1β (IL-1β) or tumour necrosis factor α (TNF-α) or decreased interleukin 1 receptor antagonist (IL-1ra) 
have been shown less consistently (36-39). A recent study (43) found significantly higher levels of 
interleukin 17 (IL-17), interferon γ (IFNγ), IL-1β, interleukin 6 (IL-6) in people with epilepsy than in 
healthy controls. Recently C-reactive protein (CRP) was also shown to be increased post-ictally in 
people with epilepsy in comparison with healthy controls (44). These cytokines are associated with 
the development of a wide range of somatic conditions. Increased serum IL-6 levels were shown to 
be an independent cardiovascular risk factor (45, 46). In healthy people, increased IL-6 was shown 
independently to predict the occurrence of other cardiovascular risk factors of myocardial infarction 
(47) and diabetes type 2 (48). In people with previous myocardial infarction, it independently 
predicts the occurrence of congestive heart failure (49) and cardiovascular deaths (50). Increased 
CRP level was found to predict the occurrence of several cancer types (ovarian (51, 52), colorectal 
(53), or lung cancer (54)), independently from other risk factors such as smoking. One hypothesis 
would be that repeated peaks of systemic inflammation induced by seizures, leading to long term 
low grade systemic inflammation, could contribute to the increased occurrence of somatic co-
morbidities. There are indeed recent suggestions that life expectancy in people with epilepsy is 
partially correlated with inflammatory markers (55). 
Shorter epilepsy duration, independently from age, was a rather counterintuitive predictor of a 
greater burden of somatic co-morbidity categories such circulatory conditions, suggesting that the 
early period after epilepsy onset is one of particular risk, which is in line with a previous study(6). 
Early referral because of associated co-morbidities seems unlikely, as the same effect was seen in the 
community cohort where people were routinely followed. A possible hypothesis would be that 
people with a greater burden of co-morbidities early in the course of epilepsy may die prematurely 
and thus not be seen later. This is also in keeping with a study(28) showing increased premature 
mortality due to co-morbidities early in the course of the disease in people with the greatest seizure 
frequency. 
In the referral centre cohort, being female was a predictor of a higher burden of somatic conditions, 
affecting endocrine/metabolic/nutritional and musculoskeletal conditions. This probably relates to 
females being at risk of osteoporosis(56) or of gender-specific conditions such as polycystic ovary 
syndrome(57) in combination with the increase probability of exposure to AEDs such as valproate in 
the large number of drugs tried (our model did not take into account specific conditions combined 
with exposure to specific medication). 
The presence of an underlying lesion (structural epilepsy) was found to protect against a spectrum of 
somatic co-morbidities in both cohorts. People without a clear cause may have been more 
thoroughly assessed at the referral centre and more concurrent diagnoses may have been reported 
in discharge summaries to maximise reimbursement, but this seems unlikely as co-morbidities were 
systemically recorded during admission before investigation results were known. A study in people 
with epilepsy without an identified structural cause found significantly larger chromosomal deletions, 
encompassing significantly more genes, than in a group of healthy controls group(58). It could be 
hypothesised that people with non-structural epilepsy (a measure limited by varying imaging 
qualities in our study) might have a stronger genetic contribution to the epilepsy, making them 
potentially more liable to harbour more somatic conditions.  
Somatic co-morbidities are commonly overlooked, possibly because of their heterogeneity, the 
presumed influence of AEDs, or because somatic co-morbidities are not felt to be related to epilepsy. 
Our results, suggesting a consistent link between seemingly unrelated somatic conditions and 
epilepsy (although they do not demonstrate it), are further evidence that epilepsy has wide 
physiological implications even in people with apparently mild epilepsy. Seizures, or their treatment, 
cannot fully explain the burden of somatic conditions, as people with mostly controlled epilepsy 
were also shown to have a significant premature mortality due to co-morbidities(13), independently 
from AED treatment(7). Effects of epileptic syndromes (especially epilepsy without structural 
abnormalities or “cryptogenic” epilepsy) should therefore be considered as not limited to the central 
nervous system, and the overall health of people with epilepsy (including those with controlled 
seizures) should be carefully evaluated. General health of patients with epilepsy should not be 
considered as unrelated to the disease and should also be a concern for the treating specialist. 
Our study has several limitations. People in the community did not undergo a comprehensive 
assessment and, for example, the prevalence of idiopathic generalised epilepsy (genetic generalised 
epilepsy) and underlying structural lesions were probably underestimated, overemphasising the 
proportion of people with epilepsy of unknown origin in the community. The assessment of co-
morbid conditions is also limited by the use of medical records; we did not directly assess somatic co-
morbidities using diagnostic tests. The retrospective design may bias the results through the varying 
degree of attention paid by the caring physicians. The cohorts were also not fully contemporary and 
both sets of data were collected over a decade; secular lifestyle changes may have been confounders 
over that period, although the predictors found seem unlikely to have been influenced by 
environmental factors over that time period. Finally, the low pseudo R2 of the multivariable analyses 
suggest that our model predicted only a small part of the variation of the burden of somatic co-
morbidities; socio-economic factors, ethnicity, lifestyle, and educational level (which were not 
available systematically in records) would probably also have explained part of the variation(10). 
Ageing is obvious also a major determinants of the burden of co-morbidities, our analyses showed 
however that the associations described were age independent. 
Conclusions 
Somatic co-morbidities are very common in people with epilepsy and do not occur randomly in 
relation to the epilepsy. Epilepsy severity is a risk factor. The increased burden of somatic co-
morbidities in people without a clear underlying brain lesion could suggest a genetic predisposition 
for the co-occurrence of epilepsy and somatic co-morbidities. Independently from age, the early 
period after epilepsy onset appears to be at particular risk, possibly because co-morbid conditions 
lead to premature mortality. Epilepsy should be considered as a systemic condition not limited to the 
CNS. Other somatic conditions should not be considered as completely unrelated to the disease and 
should also be a concern for the treating specialist. 
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Community (n= 1278) Tertiary centre (n=2016) p value 
Gender 51% male (658) 49% male (978) p=0.096 
Age (years) 48 (median, range 17-97) 35 (median, range 17-77) p<0.0001 
Year of assessment  2001 (median, range 1984-2002) 2006 (median, range 2001-2011) p<0.0001 
Epilepsy duration (years) 15 (median, range less than a year-76) 22 (median, range less than a year-64) p<0.0001 
Presence of an underlying lesion 28% (353) 45% (911) p<0.0001 
Genetic diagnosis as cause of epilepsy 1.1% (14) 2.1% (43) p=0.026 
Idiopathic generalised epilepsy 2.5% (32) 6.2% (124) p<0.0001 
Ongoing seizures* 13% (170) 100% (2016) p<0.0001 
Number of AEDs to which exposed†  1 (median, range 0-10) 7 (median, range 2-20) p<0.0001 
Intellectual disability 4.6% (59) 17% (345) p<0.0001 
Somatic co-morbidities 36% (466) 49% (987) p<0.0001 
     No somatic co-morbidity 64% (812) 51% (1029)  
     One system affected 26% (333) 31% (620)  
     Two system or more affected 10% (133) 18% (367)  
Psychiatric co-morbidities 11% (143) 23% (458) p<0.0001 
 
Table 1: Demographic and epilepsy characteristics in both cohorts. * defined as seizure(s) in the year preceding the assessment, †over entire duration of 
epilepsy 
 
 
  
Table 2 
Table 2: Predictive factors of the number of co-morbidity categories (ICD 10 Chapters), adjusted for age. To satisfy the proportionality of odds ratios 
assumption, the community cohort was split in 2 age groups (60 years and less, or more than 60 years) and age-squared was used to adjust the analysis in 
the referral centre cohort. Pseudo R2 was low in both cohorts (0.01-0.09 in the community, 0.04-0.09 in the referral centre cohort). 
  
a. factors associated with somatic comorbidities (0,1,2+) in the community cohort     
    Univariable analyses Multivariable analyses 
Associated  factors 
Odds ratio 95% Confidence interval Odds ratio 
95% Confidence 
 interval p Value 
age≤600 Longer epilepsy duration (years)1 0.98 0.96 - 0.99 0.97 0.95 - 0.99 p<0.0001 
 N=850 Presence of an underlying lesion2  0.67 1.01 - 2.19 0.57 0.38 - 0.87 p=0.007 
  
Total number (greater) of AEDs to which 
exposed3 0.88 0.79 - 0.97       
age>60 Longer epilepsy duration (years)1 0.96 0.95 - 0.98 0.96 0.94 - 0.97 p<0.0001 
 N=428 Presence of an underlying lesion2 0.45 0.31 - 0.64 0.28 0.19 - 0.43 p<0.0001 
  
Total number (greater) of AEDs to which 
exposed2 0.73 0.62 - 0.87       
0 analysis is adjusted for age (see methods). 1 unadjusted and adjusted odds ratios represents the change in odds of having 1 comorbidity versus none, 
or equivalently 2+ versus 1, when epilepsy duration increases by 1 year. 2 unadjusted and adjusted odds ratios represents the change in odds of having 
1 comorbidity versus none, or equivalently 2+ versus 1, for those with and without underlying lesions. 3 unadjusted and adjusted odds ratios represents 
the change in odds of having 1 comorbidity versus none, or equivalently 2+ versus 1, when total number of AEDs increase by 1. 
 
 
 
 
 
 
 
 
 
 
 
 
  
B .Factors associated with somatic comorbidities (0,1,2+) in the  referral centre cohort0 
 Univariable analyses Multivariable analysis 
Associated factors Odds ratio 
95% Confidence 
interval Odds ratio 
95% Confidence 
 interval p Value 
Female gender (compared with males)1 1.34 1.13 - 1.58 1.34 1.13 - 1.59 p=0.001 
Longer epilepsy duration (years)2 1.01 1.01 - 1.02 0.98 0.98 - 0.99 p<0.0001 
One family member affected3 0.81 0.65 - 1.01       
Presence of an underlying lesion4 0.61 0.52 - 0.72 0.57 0.48 - 0.68 p<0.0001 
Presence of complex partial seizures5 0.82 0.68 - 0.99       
Number of enzyme inducing AEDs to which exposed6 1.11 1.02 - 1.22       
0 analysis is adjusted for age (see methods) 1 unadjusted and adjusted odds ratios represent the change in odds of having 1 comorbidity versus none, or 
equivalently 2+ versus 1, for female and male patients. 2 unadjusted and adjusted odds ratios represent the change in odds of having 1 comorbidity 
versus none, or equivalently 2+ versus 1, when epilepsy duration increases by 1 year. 3 unadjusted and adjusted odds ratios represent the change in odds 
of having 1 comorbidity versus none, or equivalently 2+ versus 1, for those with one or no family member affected. 4 unadjusted and adjusted odds ratios 
represent the change in odds of having 1 comorbidity versus none, or equivalently 2+ versus 1, for those with and without underlying lesions.  
5 unadjusted and adjusted odds ratios represent the change in odds of having 1 comorbidity versus none, or equivalently 2+ versus 1, for those with and 
without complex partial seizures. 6 unadjusted and adjusted odds ratios represent the change in odds of having 1 comorbidity versus none, or 
equivalently 2+ versus 1, when number of enzyme inducing AEDs increase by 1. 
Table 3 Predictors of specific comorbidity categories 
  
 
 
Results are adjusted for all other predictors identified in the multivariable analysis (i.e. epilepsy duration, absence of underlying cause and age in the 
community cohort; gender, epilepsy duration, presence of underlying cause and age square in the referral centre cohort). Only co-morbidity categories 
remaining significant after correction for multiple testing are listed here. 
 
 
 
 
Figure 1: Distribution of somatic co-morbidities in both cohorts. Dark grey columns represent the referral centre cohort, light grey column the community 
cohort. Each co-morbidity category distribution was analysed using Chi-square test (or Fisher’s test as needed). 
 
 
Female gender Longer epilepsy duration Presence of an underlying lesion 
referral centre cohort referral centre cohort community cohort referral centre cohort  community cohort 
endocrine/metabolic/nutritional  - nervous system endocrine/metabolic/nutritional  circulatory  
OR: 2.01, 95% CI: 1.50-2.72  OR: 0.97, 95% CI: 0.94-0.99 OR: 0.58, 95% CI: 0.43-0.78 OR: 0.56, 95% CI: 0.38-0.84  
musculoskeletal  circulatory digestive  nervous system  
OR: 1.84, 95% CI: 1.25-2.70  OR: 0.96, 95% CI: 0.95-0.98 OR: 0.55, 95% CI: 0.39-0.79 OR: 0.42, 95% CI: 0.25-0.73 

